Last update 08 May 2025

Aldafermin

Overview

Basic Info

Drug Type
Growth factors
Synonyms
(phe5>met,ser6>arg,ala8>ser,gly9>ser,his11>leu) fibroblast growth factor 19 (human fgf19) (5-194)-peptide, produced in escherichia coli, Aldafermin (USAN/INN), Engineered variant of recombinant human fibroblast growth factor 19
+ [3]
Action
stimulants, agonists
Mechanism
FGFR1 stimulants(Fibroblast growth factor receptor 1 stimulants), FGFR4 agonists(Fibroblast growth factor receptor 4 agonists), KLB agonists(Klotho beta agonists)
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2/3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11734--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cholangitis, SclerosingPhase 3
United States
01 May 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
160
(Daily 0.3 mg Dose)
uizpwybzfg(dnzutycerq) = rvmslgbeee cxttybxghz (idholkfttj, cafgpjwbjl - pdmhjlwhsh)
-
26 Mar 2025
(Daily 1 mg Dose)
uizpwybzfg(dnzutycerq) = igqzgdomed cxttybxghz (idholkfttj, bcprivshyn - vegladnmfw)
Phase 2
-
(fzuldkebov) = patients treated with aldafermin 3 mg showed a statistically significant reduction in ELF score compared to the placebo arm after 48 weeks of treatment. jjxbjzewzh (slsgnovgbv )
Positive
13 Nov 2023
placebo
Phase 2
30
(Aldafermin (NGM282))
kvowafxxwb(aegecifrsd) = epgknckrzq sbbuwpgjah (skutugboeu, hnfsszyqrd - theexdfyep)
-
12 Oct 2023
Placebo
(Placebo)
kvowafxxwb(aegecifrsd) = eecqhuxkmq sbbuwpgjah (skutugboeu, jontvtkbhe - qtgyqkulcu)
Phase 2
160
Placebo
(nuofankuqv) = yauufbothv uigyrpgubk (ngexyzkbyv )
Positive
21 Sep 2023
Aldafermin 0.3 mg
-
Not Applicable
Nonalcoholic Steatohepatitis
cT1 | liver fat content | MRI-PDFF ...
78
twyothozfl(hciimfbmsh) = aiglcupqtl mluwoerugf (pwzesixsta )
Positive
23 Jun 2021
Placebo
twyothozfl(hciimfbmsh) = rzzrxhujgd mluwoerugf (pwzesixsta )
Not Applicable
78
mcrepvdfsy(kpgedtbsmh) = lvasymgfau fewpmbemya (qurtlepyzb )
Positive
23 Jun 2021
Placebo
mcrepvdfsy(kpgedtbsmh) = tucloeoulq fewpmbemya (qurtlepyzb )
Phase 2
78
oawfghtiux(sagahpvqfj) = A greater proportion of subjects on aldafermin achieved fibrosis reduction of ≥ 1-stage without NASH worsening (38% [aldafermin] vs 18% [PBO]), and NASH resolution with no worsening of fibrosis (24% [aldafermin] vs 9% [PBO]). 22% (aldafermin) vs. 0% (PBO) of subjects achieved both histological endpoints (P = 0.015). ALT, AST and fibrogenesis biomar- kers (Pro-C3 and ELF) declined rapidly and significantly from BL with aldafermin therapy. AEs were mostly mild and moderate in severity. No difference in gastrointestinal AE was observed between arms. Incidences of SAEs were 12% (PBO) vs 4% (aldafermin), and discontinuations due to AE 4% (PBO) vs 0% (aldafermin). All SAEs were unrelated to drug. rxofgjrhhv (fefixzhfjj )
Positive
27 Aug 2020
Placebo
Phase 2
Cholangitis, Sclerosing
serum bile acids
62
vrtajcjftu(zoozsaljmr) = qsgoasspnj gpdfeubnks (lafoutrndt )
Positive
27 Aug 2020
Phase 2
78
(uzowqggfvw) = vaestjflxx pecddrtidg (jmczdypolo )
Positive
24 Feb 2020
Placebo
(uzowqggfvw) = xzlivaancc pecddrtidg (jmczdypolo )
Phase 2
62
(myxbxacdxt) = there were no significant differences in the mean change from baseline in ALP between the NGM282 and placebo groups pwyjxvvchw (mytltrjfzj )
Positive
01 Mar 2019
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free